**Weekly Highlights**

- Overall influenza activity in the DON is **low**.
- Laboratory-positive cases and dispensed antivirals are **low** and the trend has increased over the prior 2 weeks. The percent of outpatient visits for ILI are **normal** and the trend has remained the same over the prior 2 weeks.
- Inpatient activity for both laboratory-positive cases (N=1) and inpatient dispensed antivirals (N=4) is **low**.
- Recruit laboratory-positive cases are **elevated** and **above baseline** at James A. Lovell FHCC, including **elevated** cases of influenza type B and inpatient cases.

**Influenza Surveillance Indicators**

<table>
<thead>
<tr>
<th>Overview</th>
<th>Trend</th>
<th>Activity Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory Cases</td>
<td>▲</td>
<td>Low</td>
</tr>
<tr>
<td>Dispensed Antivirals</td>
<td>▲</td>
<td>Low</td>
</tr>
<tr>
<td>ILI Outpatient Visits</td>
<td>➡</td>
<td>Normal</td>
</tr>
</tbody>
</table>

**Severity**

- Inpatient Laboratory Cases N 1 ➡ Low
- Inpatient Dispensed Antivirals N 4 ➡ Low

**Active Duty and Recruits**

- Active Duty Laboratory Cases N 19 ➝ Normal
- Active Duty Dispensed Antivirals N 25 ➝ Normal
- Recruit Laboratory Cases N 8 ➝ Elevated
- Recruit Dispensed Antivirals N 4 ➝ Elevated

**Overall Burden (Data Lagged, Week 41)**

<table>
<thead>
<tr>
<th>DON Total Influenza Cases from Laboratory, Pharmacy and Encounter Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cases: 4256, 2019 - 2020 Cases: 1350, Baseline: 4256</td>
</tr>
<tr>
<td>100% in Lab: 42.2, 64.4, 50.4</td>
</tr>
</tbody>
</table>

**Supporting Surveillance**

- **DOD Seasonal Influenza Surveillance Summary (AFHSB)**
  - Week 42 highlights: No recent updates available at this time.

- **Febrile Respiratory Illness Surveillance Report (NHRC)**
  - 18 October 2019 report highlights: No recent updates available at this time.

Data from NH Oak Harbor, Bremerton, and Lemoore; AMC Madigan and AHC Monterey; and Fairchild, Mt. Home and Travis AFB are not captured due to transition to MHS GENESIS.
• **Burden:** Laboratory-positive influenza cases (N=51) are low and below the seasonal threshold. The trend over the past two weeks has increased. The number of laboratory-positive cases has remained the same from the prior week.

• **Specimens:** Overall percent positivity is 8.1%, with 49.1% of cases identified as influenza A.

• **Severity:** One inpatient laboratory-positive case was identified in a sponsor.

• **Age:** Children ages 0-4 had the highest rate of laboratory-positive influenza cases at 4.5 cases per 100,000 persons, while adults ages 18-44 had the second highest rate at 3.4 cases per 100,000 persons.

• **Location:** James A Lovell FHCC (N=14), NMC Camp Lejeune (N=9), NHC Annapolis (N=7), and NH Jacksonville (N=5) had the highest number of laboratory-positive cases for the week.

Data sources: HL7-formatted CHCS chemistry and microbiology databases. Denominators for rates are from M2 eligibility records.
**Antiviral Surveillance**

- **Burden:** Dispensed antivirals (N=83) are low and below the seasonal threshold. The trend over the past two weeks has increased. The number of dispensed antivirals increased from the prior week by 2.3%.

- **Severity:** 3 inpatient dispensed antivirals were identified in sponsors (N=2), and a spouse (N=1).

- **Location:** James A Lovell FHCC (N=12), NMC Camp Lejeune (N=11), Walter Reed Natl Mil Med Cntr (N=8), and NH Guantanamo Bay (N=6) had the highest number of dispensed antivirals for the week.

Data sources: HL7-formatted CHCS chemistry and microbiology databases.

**Top MTFs, Dispensed Antivirals, Week 42**

- James A Lovell FHCC (N=12)
- NMC Camp Lejeune (N=11)
- Walter Reed Natl Mil Med Cntr (N=8)
- NH Guantanamo Bay (N=6)

**Top MTFs, Dispensed Antivirals, 2019 - 2020 Season**

- NH Pensacola (N=42)
- NMC Camp Lejeune (N=35)
- James A Lovell FHCC (N=18)
- NH Jacksonville (N=18)
- NH Okinawa (N=17)
- NMC Portsmouth (N=16)

Note: Season counts are since Week 37.

**Influenza-Like Illness (Data Lagged, Week 41)**

- **All outpatient:** Influenza-like illness (ILI) activity is normal. The percentage of outpatient medical encounters due to ILI was 2.8% in Week 41, below the surveillance threshold of 4.1%.

- **Note:** ILI activity is used to indicate the burden of ILI on healthcare resources.

Data source: CAPER

**Outpatient Medical Encounters due to ILI, Week 41**

**Antiviral Prophylaxis**

- **Treatment:** The majority (81.4%) of antiviral prescriptions in Week 42 were for treatment of influenza or influenza symptoms.

- **Prophylaxis:** 18.6% of antiviral prescriptions in Week 42 were for prevention of influenza or influenza symptoms.

Data source: HL7-formatted CHCS pharmacy databases

**Antiviral Prophylaxis Prescriptions**
DON Active Duty and Recruits

- **AD Laboratory Cases**: 8 laboratory-positive cases were identified among AD Sailors (N=6) and Marines (N=2).
- **AD Dispensed Antivirals**: 13 dispensed antivirals were identified among AD Sailors (N=12) and Marines (N=1).
- **Recruits**: 14 laboratory-positive cases and 12 dispensed antivirals were identified among recruits.
- **Location (Active Duty)**: Laboratory-positive cases among active duty Sailors or Marines occurred most frequently at James A Lovell FHCC (N=2).
- **Location (Recruits)**: Laboratory-positive cases among recruit Sailors or Marines occurred most frequently at James A Lovell FHCC (N=12), and NH Beaufort (N=2).
- **Vaccination Status**: 1 AD laboratory-positive case (12.5%) had a vaccination record more than fourteen days prior to infection.

Data Sources: HL7-formatted CHCS chemistry, microbiology and pharmacy databases, MRRS and ITS.

Laboratory-Positive Cases Among DON Active Duty Service Members, 2019 - 2020 Season

<table>
<thead>
<tr>
<th></th>
<th>Laboratory</th>
<th>Dispensed AVs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Week 42</td>
<td>Season</td>
</tr>
<tr>
<td>Total Cases</td>
<td>22</td>
<td>97</td>
</tr>
<tr>
<td>Navy AD</td>
<td>6</td>
<td>47</td>
</tr>
<tr>
<td>Marine Corps AD</td>
<td>2</td>
<td>20</td>
</tr>
<tr>
<td>Navy Recruit</td>
<td>12</td>
<td>28</td>
</tr>
<tr>
<td>Marine Corps Recruit</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

Note: Season counts are since Week 37.

In the News

- Single dose Xofluza has been approved by the FDA for patients 12 and over who are at high risk for influenza complications. [Details.](#)

Methods and Data Sources

The Influenza SITREP methods can be found [here.](#)

- HL7 formatted CHCS data from microbiology and chemistry data are available from 2004 to present. HL7 formatted CHCS data from pharmacy databases are available from 2006 to present.
- Data from NH Oak Harbor, Bremerton, and Lemoore; AMC Madigan and AHC Monterey; and Fairchild, Mt. Home and Travis AFB are not captured due to transition to MHS GENESIS.
- Laboratory-positive and AV baselines are calculated as an average of the 2015-2016, 2016-2017, and 2017-2018 seasons.
- ILI threshold is calculated based on the off-season percentage outpatient visits for the 2015-2016, 2016-2017, and 2017-2018 seasons, plus two standard deviations.
- ILI encounters are defined as those where an ILI ICD-10-CM code, per AFHSB, is found in any diagnostic position. The ICD-10-CM codes in the AFHSB definition include: B97.89, H66.9, H66.90, H66.91, H66.92, H6693, J00, J01.9, J01.90, J06.9, J09, J09.X, J09.X1, J09.X2, J09.X3, J09.X9, J10, J10.0, J10.00, J10.01, J10.08, J10.1, J10.2, J10.8, J10.81, J10.82, J10.83, J10.89, J11, J11.0, J11.00, J11.08, J11.1, J11.2, J11.8, J11.81, J11.82, J11.83, J11.89, J12.89, J12.9, J18, J18.1, J18.8, J18.9, J20.9, J40, R05, R50.9
- The ”Overall Burden” and ILI figures are lagged one week due to encounter data availability.
- Prepared by the EpiData Center on 23OCT19.